GW Pharmaceuticals initiates first Phase 3 pivotal trial for epidiolex in Dravet syndrome

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces it...